http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
강전홍(Kang Jeon Hong),유광민(Yu Kwang Min),김한준(Kim Han Jun),한상옥(Han Sang Ok),박강식(Park Kang Sic),이세현(Lee Sae Hun) 대한전기학회 2007 대한전기학회 학술대회 논문집 Vol.2007 No.4
금속의 전기 비저항 측정방법은 일반적으로 4단자, van der Pauw, Four-Point Probe(FPP), eddy current 방법 등이 있다. 이들의 측정방법들은 각각 다르지만 동일한 시료에 대한 전기 비저항 측정값은 거의 같은 결과를 나타내어야 한다. 금속 전기 비저항의 정밀측정에 대한 연구를 위하여 비자성 금속인 STS 316 시료를 선정하여 측정한 결과 4단자와 van der Pauw 방법으로 측정된 비저항은 각각 75.86 ㎕ · ㎝(2.273 %IACS), 75.80 ㎕ · ㎝(2.275 %IACS)이며, 측정 불확도는 0.25 %로서 거의 동등한 결과를 나타냈고, Four Point Probe(FPP) 방법으로 측정된 비저항은 75.36 ㎕ · ㎝(2.288 %IACS), 측정 불확도는 0.45 %, eddy current 방법으로 측정된 비저항은 76.63 ㎕ · ㎝(2.25 %IACS), 측정 불확도는 0.64 %로 나타났다.
The role of hedgehog signaling during gastric regeneration.
Kang, Dae-Hwan,Han, Myoung-Eun,Song, Moo-Ho,Lee, Young-Suk,Kim, Eun-Hee,Kim, Hyun-Jung,Kim, Gwang-Ha,Kim, Dong-Heon,Yoon, Sik,Baek, Sun-Yong,Kim, Bong-Seon,Kim, Jae-Bong,Oh, Sae-Ock Springer International 2009 Journal of gastroenterology Vol.44 No.5
<P>Hedgehog signaling plays critical roles during embryonic development. It is also involved in tissue regeneration and carcinogenesis in various adult tissues. Moreover, it regulates the maintenance of cancer stem cells and adult stem cells. Although hedgehog signaling is important in gastric carcinogenesis, its role in gastric regeneration has not been previously examined. In the present study, we evaluated the expression and roles of hedgehog signaling during gastric regeneration.</P>
Histological Features Affecting Hepatocarcinogenesis in Chronic Viral Hepatitis
( Sae Hwan Lee ),( Young Hwa Chung ),( Dan Bi Lee ),( Yoon Seon Lee ),( Hyun Ju Min ),( Dong Dae Seo ),( Kang Mo Kim ),( Young Suk Lim ),( Han Chu Lee ),( Eun Sil Yu ),( Yung Sang Lee ),( Dong Jin Suh 대한간학회 2007 Clinical and Molecular Hepatology(대한간학회지) Vol.13 No.3(S)
한승세,이성행,강덕식 慶北大學校 醫科大學 1982 慶北醫大誌 Vol.23 No.2
경북의대 흉부외과학 교실에서 1982년도에 개심술을 시행한 환자 중 무작위로 10예를 선택하여 혈액응고인자를 검사한 바 다음과 같은 성적을 얻었다. 혈액응고인자 즉 Ⅰ,Ⅱ,Ⅴ, 및 Ⅷ의 활성치는 모두 관류초기 및 관류말기에 심한 감소를 보였고 (p<0.001) 관류후 2-4시간에 대조치인 전신마취 중의 검사치로 회복하는 추세를 보였다. 술후 출혈량은 517±329ml/M^2/day 였으며 결론적으로 관류중 혈액응고인자의 심한 감소현상이 술후 비교적 빠른시간내에 관류전치로 회복하고 있는 것으로 보아 술후 과도한 출혈의 중요한 원인이 되지는 않는 것으로 본다. This study was performed to analyze the magnitude and duration of changes in certain clotting factors during and following cardiopulmonary bypass and to correlate these changes with excessive bleeding, if it occurred. Ten cases of patients were randomly selected for this study. They were examined factor assays such as Ⅰ,Ⅱ,Ⅴ, and Ⅷ, using a Coag-stat BC-2210 Blood Coagulation Analyzer. Blood samples were obtained during general anesthesia, at the beginning of the bypass, at the end of bypass and 2-4 hours after bypass. Factor activities such as Ⅰ,Ⅱ,Ⅴ, and Ⅷ decreased markedly during bypass(p<0.001) and returned promptly to control levels which are values during general anesthesia at 2-4 hours after bypass. Postoperative bleeding presented as 517±329ml/M^2/day.
Kang, Su-Jin,Song, Chang-Hyun,Kim, Jong-Kyu,Chun, Yoon-Seok,Han, Chang-Hyun,Lee, Young-Joon,Ku, Sae-Kwang Society of Preventive Korean Medicine 2018 대한예방한의학회지 Vol.22 No.2
Objectives : In present study, therefore, possible beneficial pharmacological activities of standard potato protein extracts (SPE) were observed on the mild diabetic obese mice. Methods : After end of 12 weeks of continuous oral administrations of three different dosages of SPE 400, 200 and 100 mg/kg, or metformin 250 mg/kg, analyzed the hepatoprotective, hypolipidemic, hypoglycemic, nephroprotective and anti-obesity effects, separately. In addition, liver antioxidant defense systems were additionally measured with lipid metabolism-related genes expressions and hepatic glucose-regulating enzyme activities for action mechanism. Results : All of diabetes and related complications including obesity were significantly inhibited by treatment of SPE 400, 200 and 100 mg/kg, dose-dependently, and they also dramatically normalized the hepatic lipid peroxidation and depletion of liver endogenous antioxidant defense system, the changes of the hepatic glucose-regulating enzyme activities, also changes of the lipid metabolism-related genes expressions including hepatic $AMPK{\alpha}1$ and $AMPK{\alpha}2$ mRNA expressions, dose-dependently. Especially, SPE 200 mg/kg constantly showed favorable inhibitory activities against type II diabetes and related complications as comparable to those of metformin 250 mg/kg in HFD mice, respectively. Conclusions : The present work demonstrated that SPE 400, 200 and 100 mg/kg showed favorable anti-diabetic and related complications including obesity refinement activities in HFD mice, through AMPK upregulation mediated hepatic glucose enzyme activity and lipid metabolism-related genes expression, antioxidant defense system and pancreatic lipid digestion enzyme modulatory activities.
Han, Joong Tark,Kim, Jun Suk,Jo, Sae Byeok,Kim, Sung Hun,Kim, Jong Soo,Kang, Boseok,Jeong, Hee Jin,Jeong, Seung Yol,Lee, Geon-Woong,Cho, Kilwon The Royal Society of Chemistry 2012 Nanoscale Vol.4 No.24
<P>Modulation of electronic structures and surface properties of transparent carbon nanotube films is a challenging issue for their application in optoelectronic devices. Here, we report, for the first time, that graphene oxide (GO) nanosheets play the role of a p-doping agent and surface energy modifier of single-walled carbon nanotube (SWCNT)-based transparent conducting electrodes (TCEs). The deposition of highly oxidized, small-sized (i.e., diameter of less than 500 nm) GO nanosheets onto a SWCNT network film reduces the sheet resistance of the pristine film to 60% of its original value by p-doping. The modified TCEs exhibit an outstanding optoelectronic feature of high conductivity with high transparency. Moreover, the wettability of the electrode surface was also noticeably increased, which is advantageous for the solution-based processing of organic electronics. Furthermore, the organic photovoltaic (OPV) cells with the GO-doped SWCNT anodes on flexible substrates were successfully demonstrated. In stark contrast to a power conversion efficiency of 0.44% for pristine SWCNT anodes, GO-doped SWCNT anodes show a drastically enhanced power conversion efficiency of 2.7%.</P>
( Sae Hwan Lee ),( Il Han Song ),( Ran Noh ),( Ha Yan Kang ),( Soon Young Ko ),( Eom Seok Lee ),( Seok Hyun Kim ),( An Na Kim ),( Byung Seok Lee ),( Hee Bok Chae ),( Hong Soo Kim ),( Young Woo Kang ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Backgroud/Aims: Sorafenib, an oral multikinase inhibitor with antiangiogenic and antiproliferative properties, showed significant benefits in terms of time to progression and survival in patients with advanced hepatocellular carcinoma (HCC) in large clinical trials. The aim of this study was to investigate treatment outcomes of sorafenib in real clinical fields. Methods: From August 2007 to March 2012, patients with advanced HCC who received sorafenib in seven referral hospitals in Daejeon-Chungcheong province were retrospectively enrolled for the evaluation of tolerability, treatment response and survival following sorafenib administration. Treatment response was radiologically assessed by RECIST 1.1. Results: Among a total of 123 patients enrolled, sixty-eight (55%) patients received prior treatment and 74 (60%) patients had Child-Pugh A cirrhosis. One hundred-three (84%) patients were BCLC stage C; Ninety-three (76%) patients were modified UICC IV. The median duration of sorafenib treatment was 67 (14-452) days. Seventy-three (60%) patients have experienced adverse events, resulting in transient dose reduction or cessation. Treatment interruption was brought by disease progression (36%), adverse events (21%), hepatic failure (10%), and financial burden (7%). Complete response, partial response and stable disease were seen in none, 1% and 18%, respectively, and disease control rate was 29%. Median time to progression was 84 days and overall median survival was 139 days. Patients with decompensated cirrhosis showed a shorter median time to progression (61 vs. 104 days, p=0.036) and overall survival (63 vs. 168 days, p<0.001) compared to those with compensated cirrhosis. Child-Pugh class B/C (p=0.027) and prior treatment (p=0.015) were independent risk factors for survival. Conclusions: Clinical outcomes of sorafenib treatment in patients with advanced HCC were comparable to those of previous studies. The function of hepatic reserve and history of previous treatment were independent factors affecting survival.